BIRC5 and Hepatic fibrosis: In the present study, we reported that targeting survivin in activated HSCs inhibits its ECM protein expression, proliferation, migration, and contraction ability, the key features of fibrogenic HSCs, which eventually halt liver fibrosis progression.